ArticleMolecular oncology2015
KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.
Dominic Leiser et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papercites it